DBV Technologies | DBVT - Equity Capital And Reserves


DBV Technologies reported $52.85M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Alnylam Pharmaceuticals USD 789.18M 555.28M Dec/2025
Amarin USD 458.89M 6.03M Sep/2025
BioCryst Pharmaceuticals USD -119.15M 268.74M Dec/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
DBV Technologies USD 52.85M 33.37M Sep/2025
Esperion Therapeutics USD -301.96M 149.4M Dec/2025
Galectin Therapeutics USD -83.87M 11.06M Jun/2024
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
Neurocrine Biosciences USD 3.25B 249.5M Dec/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
United Therapeutics USD 7.1B 506M Dec/2025